Vorapaxar, combination antiplatelet therapy, and stroke

Journal of the American College of Cardiology

Volumn 64, Issue 22, 2014, Pages 2327-2329

  Hart, Robert G ^a   Halperin, Jonathan L ^b   Weitz, Jeffrey I ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

acute coronary syndrome; antiplatelet; intracerebral hemorrhage; PAR 1 receptor; peripheral arterial disease; platelet activation; platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; THIENOPYRIDINE DERIVATIVE; VORAPAXAR; LACTONE; PYRIDINE DERIVATIVE; THROMBIN RECEPTOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; HEART INFARCTION; HUMAN; NOTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK BENEFIT ANALYSIS; RISK FACTOR; STENT THROMBOSIS; ANTAGONISTS AND INHIBITORS; CORONARY THROMBOSIS; DRUG ELUTING STENT; FEMALE; MALE; STROKE;

BRAIN ISCHEMIA; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; LACTONES; MALE; PYRIDINES; RECEPTORS, THROMBIN; STROKE;

EID: 84919459944     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.09.038     Document Type: Editorial

References (19)

1. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients BMJ 324 2002 71 86
2. J.W. Eikelboom, J. Hirsh, and F.A. Spencer Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines Chest 141 Suppl 2012 e89S e119S
3. Y. Wang, Y. Wang, X. Zhao CHANCE Investigators Clopidogrel with aspirin in acute minor stroke or transient ischemic attack N Engl J Med 369 2013 11 19
4. H.C. Diener, J. Bogousslavsky, L.M. Brass MATCH Investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attach in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 2004 331 337
5. SPS3 Investigators O.R. Benavente, R.G. Hart, and L.A. McClure Effects of clopidogrel added to aspirin in patients with recent lacunar stroke N Engl J Med 367 2012 817 825
6. S.J. Connolly, J. Pogue, R.G. Hart for the ACTIVE Investigators Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
7. T.H. Wang, D.L. Bhatt, K.A. Fox CHARISMA Investigators An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial Eur Heart J 28 2007 2200 2207
8. A. Dasgupta, S.R. Steinhubl, D.L. Bhatt CHARISMA Investigators Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the CHARISMA trial) Am J Cardiol 103 2009 1359 1363
9. D.A. Morrow, E. Braunwald, M.P. Bonaca TRA 2P-TIMI 50 Steering Committee and Investigators Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
10. U.S. Food and Drug Administration. FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients. FDA News Release. May 18, 2014. Silver Spring, MD: U.S. Food and Drug Administration. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm?source. Accessed September 16, 2014.
11. M.P. Bonaca, B.M. Scirica, and E. Braunwald New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2°P-TIMI 50 trial J Am Coll Cardiol 64 2014 2318 2326
12. M.P. Bonaca, B.M. Scirica, and E. Braunwald Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2°P-TIMI 50 trial J Am Coll Cardiol 64 2014 2309 2317
13. D.A. Morrow, M.J. Alberts, J.P. Mohr Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Steering Committee and Investigators Efficacy and safety of vorapaxar in patients with prior ischemic stroke Stroke 44 2013 691 698
14. SPS3 Study Group O.R. Benavente, C.S. Coffey, and R. Conwit Blood pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial Lancet 382 2013 507 515
15. B.M. Scirica, M.P. Bonaca, E. Braunwald TRA 2°P-TIMI 50 Steering Committee Investigators Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial Lancet 380 2012 1317 1324
16. M. Lee, J.L. Saver, and K.S. Hong Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists Stroke 43 2012 3189 3195
17. S. Palacio, R.G. Hart, and L.A. Pearce Effect of additional of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized trials Int J Stroke 2013 May 22 [E-pub ahead of print]
18. P. Tricoci, Z. Huang, C. Held TRACER Investigators Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
19. C.T. Ruff, R.P. Giugliano, and E. Braunwald Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials Lancet 383 2014 955 962